The NxTAG® Respiratory Pathogen Panel is a next generation closed tube, molecular assay with comprehensive coverage designed to improve your laboratory workflow and enable your laboratory to simultaneously detect 20 respiratory pathogens, accommodating the higher throughput required to respond to changes on demand.
The NxTAG Respiratory Pathogen Panel streamlines respiratory testing:
|NxTAG Respiratory Pathogen Panel Targets (US-IVD)|
|Influenza A H1||Parainfluenza virus 1||Coronavirus HKU1|
|Influenza A H3||Parainfluenza virus 2||Coronavirus NL63|
|Influenza B||Parainfluenza virus 3||Coronavirus 229E|
|Respiratory Syncytial Virus A||Parainfluenza virus 4||Coronavirus OC43|
|Respiratory Syncytial Virus B||Human Metapneumovirus||Human Bocavirus|
|Chlamydophila pneumoniae||Mycoplasma pneumoniae|
|NxTAG® Respiratory Pathogen Panel Ordering Information|
|Luminex Online Order Management|
|Fax (Europe, Middle East, India, Asia):||+31 (0)73 800 1998|
|Product Name||Kit Size||Registration Status||Part Number|
|NxTAG® Respiratory Pathogen Panel||96 Tests||US-IVD||I051C0447|
Note: Luminex manufactures and distributes products mentioned in the reference materials provided in this section. The reference materials may mention use of product that has not been approved or cleared by regulatory agencies in your region or territory. Luminex is providing reference materials for customer information and does not recommend using the product inconsistent with the product’s intended use and labeling.
* This product is for Research Use Only. Not for use in diagnostic procedures. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.
NxTAG® Respiratory Pathogen Panel (US-IVD) — Sales Sheet
NxTAG® Respiratory Pathogen Panel (RPP) BioFire Comparison — Product Information
NxTAG Respiratory Pathogen Panel (RPP) Genmark Comparison – Product Information
Detection of Influenza A H1 Subtype, Parainfluenza Viruses, Coronaviruses, Adenovirus, Enterovirus D68, Chlamydophila Pneumoniae and Mycoplasma Pneumoniae with Luminex NxTAG Respiratory Pathogen Panel (For IVD Use) in Clinical and Contrived Specimens — Poster
For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.
Intended Use (US-IVD):
NxTAG® Respiratory Pathogen Panel is a qualitative test intended for use on the Luminex® MAGPIX® Instrument for the simultaneous detection and identification of nucleic acids from multiple respiratory viruses and bacteria extracted from nasopharyngeal swabs collected from individuals with clinical signs and symptoms of a respiratory tract infection. The organism types and subtypes detected by the test are Influenza A, Influenza A H1, Influenza A H3, Influenza B, Respiratory Syncytial Virus A, Respiratory Syncytial Virus B, Coronavirus 229E, Coronavirus OC43, Coronavirus NL63, Coronavirus HKU1, Human Metapneumovirus, Rhinovirus/Enterovirus, Adenovirus, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, Parainfluenza virus 4, Human Bocavirus, Chlamydophila pneumoniae, and Mycoplasma pneumoniae.
The test is indicated as an aid in the detection and identification of viral and bacterial agents causing respiratory tract infections in symptomatic adult and pediatric patients, who are either hospitalized, admitted to emergency departments or who are outpatients with suspected respiratory tract infection.
The results of this test should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Negative results in the setting of a respiratory illness may be due to infection with pathogens not detected by this test or lower respiratory tract infection that is not detected by a nasopharyngeal swab specimen. Positive results do not rule out co-infection with other pathogens. The agent detected may not be the definite cause of disease. The use of additional laboratory testing (e.g. bacterial and viral culture, immunofluorescence, and radiography) and clinical presentation must be taken into consideration in order to obtain the final diagnosis of respiratory tract infection.
Performance characteristics for influenza A were established using specimens obtained during the 2013/2014 and 2014/2015 influenza seasons when influenza A/H3 and A/H1 were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health departments for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.